Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
Source: View publication →
The CARMELINA trial demonstrated that adding linagliptin to standard care in adults with type 2 diabetes and high cardiovascular and renal risk is cardiovascularly safe and does not increase the risk of hospitalization for heart failure or renal progression compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The trial confirms the cardiovascular safety profile of linagliptin in a high-risk population of patients with type 2 diabetes and comorbid cardiovascular or renal disease, providing clinicians confidence in its use without exacerbating heart failure or renal risk.
Historical Context
Following regulatory requirements for cardiovascular outcome trials (CVOTs) for all new glucose-lowering agents, CARMELINA was designed to assess the safety of linagliptin. It specifically targeted a high-risk population with established cardiorenal disease, a group often underrepresented in earlier diabetes trials, to address concerns about the class effect of DPP-4 inhibitors on heart failure and kidney safety.
Guided Discussion
High-yield insights from every perspective
What is the mechanism of action of linagliptin, and what unique pharmacokinetic property makes it particularly relevant for the high-risk renal population studied in the CARMELINA trial?
Key Response
Linagliptin is a DPP-4 inhibitor that prevents the breakdown of incretin hormones like GLP-1 and GIP. Unlike other DPP-4 inhibitors (such as sitagliptin or saxagliptin), linagliptin is primarily excreted via the enterohepatic system (bile and feces) rather than the kidneys. This eliminates the need for dose adjustment across all stages of chronic kidney disease (CKD), which was a central focus of the CARMELINA trial's safety assessment.
The SAVOR-TIMI 53 trial with saxagliptin raised concerns about a potential class-wide risk of hospitalization for heart failure (hHF) with DPP-4 inhibitors. How do the CARMELINA results influence your clinical decision-making when selecting a glucose-lowering agent for a patient with T2DM and high cardiovascular risk?
Key Response
CARMELINA provided critical evidence that linagliptin is safe regarding heart failure, showing no increase in hHF (HR 0.90) compared to placebo. This differentiates it from saxagliptin and alogliptin. For residents, this means linagliptin can be used safely in patients with established cardiovascular disease or CKD without the specific heart failure concerns that plague other agents in the same class, though it remains secondary to SGLT2 inhibitors or GLP-1RAs if heart failure or renal protection is the primary goal.
While CARMELINA demonstrated cardiovascular safety (non-inferiority), it did not show a 'superiority' benefit for renal outcomes despite preclinical data suggesting anti-fibrotic effects of DPP-4 inhibition. How should a subspecialist reconcile these findings with the 'superiority' renal results seen in SGLT2 inhibitor trials like CREDENCE or DAPA-CKD?
Key Response
CARMELINA was designed primarily as a safety (non-inferiority) trial in a population with very advanced CKD (including eGFR down to 15). The neutrality of the composite renal endpoint (sustained ESRD, 40% GFR decline, or renal death) suggests that while linagliptin is safe, it lacks the potent hemodynamically-mediated and metabolic-protective effects of SGLT2 inhibitors. For a fellow, this highlights that linagliptin’s role in CKD is 'renal-neutral' glucose management rather than active 'renoprotection' or slowing disease progression.
In the context of 'value-based care,' how does the CARMELINA trial support the role of linagliptin for elderly patients with multi-morbidity and varying levels of renal function compared to more modern 'disease-modifying' therapies?
Key Response
Linagliptin offers a 'simplification' strategy. CARMELINA's inclusion of patients with high CV risk and advanced CKD (often excluded from other trials) proves that linagliptin is a safe 'set-and-forget' drug. It does not require GFR monitoring for dosing, has low hypoglycemia risk, and is weight-neutral. For an attending, this trial justifies linagliptin as a preferred agent for frail patients where the priority is avoiding harm (hypoglycemia, volume depletion, or heart failure exacerbation) while maintaining glycemic targets.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
CARMELINA utilized a non-inferiority margin of 1.3 for the upper bound of the 95% confidence interval for the primary MACE endpoint. Critique the choice of this margin and the implications of the high baseline CV event rate in this cohort for the statistical power of the trial.
Key Response
The 1.3 margin was the standard FDA requirement for CVOTs post-2008. Given that CARMELINA's population had extremely high risk (high CKD prevalence), the trial was well-powered to achieve a narrow confidence interval (0.81 to 1.14), which strongly supported safety. However, because the trial was driven by safety events, the PhD-level critique would focus on whether the 'neutral' renal findings were a result of the trial being underpowered for superiority or if the follow-up duration (median 2.2 years) was insufficient to see a divergence in renal outcomes in a population already at advanced stages of decline.
As a reviewer, what concerns would you raise regarding the generalizability of CARMELINA’s findings, specifically the 'neutral' heart failure signal, given the high prevalence of baseline heart failure in the study cohort compared to earlier DPP-4 inhibitor trials?
Key Response
An editor would flag that CARMELINA’s population was specifically enriched for high CV and renal risk, yet it showed an HR of 0.90 for hHF (numerically favoring linagliptin). This 'robustness' against the saxagliptin signal is a key editorial point. However, a reviewer would also ask if the frequent use of other background therapies (like ACE inhibitors or beta-blockers) in 2019 clinical practice could have masked potential signals or if the trial's design successfully mitigated the 'detection bias' for heart failure seen in earlier studies.
How does CARMELINA specifically address the gaps in the ADA/EASD consensus reports regarding the use of DPP-4 inhibitors in patients with an eGFR below 30 mL/min/1.73m², and should the 'heart failure' warning be removed from the class as a whole?
Key Response
The ADA/EASD guidelines emphasize SGLT2i and GLP-1RAs for high-risk patients. CARMELINA provides the highest level of evidence (Level 1A) for linagliptin's safety in the GFR <30 group, where SGLT2i options were previously limited. Regarding the class warning, CARMELINA (along with TECOS) suggests the heart failure risk is NOT a class effect. Therefore, guidelines should distinguish between 'safe' DPP-4s (linagliptin, sitagliptin) and those with a 'caution' or 'contraindication' in heart failure (saxagliptin, alogliptin).
Clinical Landscape
Noteworthy Related Trials
SAVOR-TIMI 53 Trial
Tested
Saxagliptin
Population
T2DM patients with history of or risk factors for CV disease
Comparator
Placebo
Endpoint
3-point MACE
EMPA-REG OUTCOME Trial
Tested
Empagliflozin
Population
T2DM patients with high CV risk
Comparator
Placebo
Endpoint
3-point MACE
TECOS Trial
Tested
Sitagliptin
Population
T2DM patients with established cardiovascular disease
Comparator
Placebo
Endpoint
4-point MACE
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis